Indian stocks: Visit www.stage2stocks.com →

DataMeds AI, Inc.

Stage 1 · Basing · week 3

As of Oct 22, 2026, DataMeds AI is in Stage 1, the basing phase, now in week 3 (since Oct 5, 2026). It closed at $2.30, 96.0% below its 52-week high and below its 200-day average, which is falling.

DataMEDS AI, Inc. operates as a health IT company in the United States. More about the company

$2.30
-15.13% today
$10.4M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Basing, not in an uptrend yet

Setup score

—

Momentum

Steady

Edge

—

Is MEDS early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2025-02-21 → 2026-10-22
S? 41w
S4 43w
2025-02-212026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 41w → S4 43w → S1 3w current
Total tracked: 87 weeks across 3 stage runs.

MEDS among Medical Distribution9th of 11 by relative strength

All 11 →
Stocks in Medical Distribution ranked by relative strength, with stage and one-month change
#StockStageRS1M
1FOCLStage 4 · wk 192−12.4%
2CAHStage 2 · wk 190+15.8%
3HSICStage 3 · wk 179+1.1%
4MCKStage 2 · wk 776+15.0%
5CORStage 2 · wk 458+8.4%
6AHGStage 4 · wk 1636+58.4%
7YIStage 4 · wk 1632−17.3%
8COSMStage 1 · wk 713−37.8%
9MEDSStage 1 · wk 38−39.9%
vs 52W High
-96.0%
$0.85 lo$57.50 hi
96.0% below 52W high
Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.
Stage Maturity
Week 3
1w13w26w
Week 3, early base
How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.
vs 200 DMA
-64.2%
200 DMA: $6.42 · sloping down
Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.
Rel Volume
0.11x
vs 50-day avg
Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-39.9%
3M
-27.4%
6M
-66.2%
YTD
-89.4%
1Y
-87.2%
Scan Membership
Not in any current scan.
Recent Stage Timeline
2026-10-22S1
Wk 3 · Vol 0.11x
2026-10-21S1
Wk 3 · Vol 0.02x
2026-10-20S1
Wk 3 · Vol 0.05x
2026-10-19S1
Wk 3 · Vol 0.51x
2026-10-16S1
Wk 2 · Vol 0.04x
2026-10-15S1
Wk 2 · Vol 0.03x
2026-10-14S1
Wk 2 · Vol 0.08x
2026-10-13S1
Wk 2 · Vol 0.11x
2026-10-12S1
Wk 2 · Vol 2.75x
2026-10-09S1
Wk 1 · Vol 0.06x
2026-10-08S1
Wk 1 · Vol 1.89x
2026-10-07S1
Wk 1 · Vol 0.05x
Moving averages & range
50 DMA
$2.39
200 DMA
$6.42
52W High
$57.50
52W Low
$0.85
5D Low
$2.30
Resistance levels (recent highs)
20d High
$4.06
60d High
$6.07
120d High
$8.70
250d High
$57.50
Next resistance
+76.5%
to 20d High
Dividend Yield
0.00%
P/B -0.3

DataMeds AI: quick answers

What stage is DataMeds AI in?

As of Oct 22, 2026, DataMeds AI (MEDS) is in Stage 1, the basing phase. It entered Stage 1 on Oct 5, 2026 and is in week 3. What the four stages mean

Is DataMeds AI in an uptrend?

Not yet. DataMeds AI is in Stage 1, a base that can come before an uptrend. It trades 64.2% below its 200-day average, which is falling.

How far is DataMeds AI from its 52-week high?

DataMeds AI closed at $2.30 on Oct 22, 2026, 96.0% below its 52-week high of $57.50. Its 52-week low is $0.85.

How has DataMeds AI performed over the past year?

As of Oct 22, 2026, DataMeds AI is down 87.2% over the past year and down 89.4% so far in 2026.

Which sector and industry is DataMeds AI in?

DataMeds AI is in the Medical Distribution industry, part of the Health Care sector.

About this companyHealth Care· Medical Distribution

DataMEDS AI, Inc. operates as a health IT company in the United States. The company focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent, and telemedicine business units to deliver an enhanced healthcare experience for consumers. It offers tools, such as the EinsteinRx, a pharmacy dispensing AI platform; the PharmacyChain, a smart contracts platform; Patient Rx Adherence Tool; and HubRx AI. It also operates as a pharmacy distributor; and provides clinical concierge services. DataMEDS AI, Inc., through its subsidiary develops and delivers a portfolio of products to guide physicians and patients with difficult clinical decisions throughout the cancer care continuum. In addition, the company develops and provides functional precision medicine oncology platform. The company was formerly known as Wellgistics Health, Inc. and changed its name to DataMEDS AI, Inc. in July 2026. DataMEDS AI, Inc. was incorporated in 2022 and is based in Tampa, Florida.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.